Iatrogenic creutzfeldt-Jakob disease, final assessment

Emerging Infectious Diseases

Volumn 18, Issue 6, 2012, Pages 901-907

  Brown, Paul ^a   Brandel, Jean Philippe ^b   Sato, Takeshi ^c   Nakamura, Yosikazu ^d   MacKenzie, Jan ^e   Will, Robert G ^e   Ladogana, Anna ^f   Pocchiari, Maurizio ^f   Leschek, Ellen W ^g   Schonberger, Lawrence B ^h  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^b INSERM   (France)

^c Nanohana Clinic   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

^f ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADOTROPIN; GROWTH HORMONE;

ARTICLE; BLOOD TRANSFUSION; CHRONIC WASTING DISEASE; CLINICAL FEATURE; CORNEA TRANSPLANTATION; DISINFECTION; DNA POLYMORPHISM; DURA MATER; ELECTROENCEPHALOGRAPHY; ERYTHROCYTE CONCENTRATE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; IATROGENIC CREUTZFELDT JAKOB DISEASE; INCIDENCE; INCUBATION TIME; INSTRUMENT STERILIZATION; NEEDLE; PRION; RISK; SURGICAL INSTRUMENT;

CREUTZFELDT-JAKOB SYNDROME; DRUG CONTAMINATION; DURA MATER; EQUIPMENT CONTAMINATION; HUMAN GROWTH HORMONE; HUMANS; IATROGENIC DISEASE; INCIDENCE; TRANSPLANTS;

EID: 84861220384     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1806.120116     Document Type: Article

References (28)

1. Duffy P, Wolf J, Collins G, DeVoe AB, Streeten B, Cowen D. Letter: possible person-to-person transmission of Creutzfeldt-Jakob disease. N Engl J Med. 1974;290:692-3. http://dx.doi.org/10.1056/NEJM197403212901220
2. Brown P, Brandel J-P, Preece M, Sato T. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology. 2006;67:389-93. http://dx.doi.org/10.1212/01.wnl.0000231528.65069.3f
3. Brown P. Human growth hormone therapy and Creutzfeldt-Jakob disease: a drama in three acts. Pediatrics. 1988;81:85-92.
4. Abrams JY, Schonberger LB, Belay ED, Maddox RA, Leschek EW, Mills JL, et al. Lower risk of Creutzfeldt-Jakob disease in pituitary growth hormone recipients initiating treatment after 1977. J Clin Endocrinol Metab. 2011;96:E1666-9. http://dx.doi.org/10.1210/jc.2011-1357
5. Wakisaka Y, Santa N, Doh-ura K, Kitamoto T, Ibayashi S, Iida M, et al. Increased asymmetric pulvinar magnetic resonance imaging signals in Creutzfeldt-Jakob disease with florid plaques following a cadaveric dura mater graft. Neuropathology. 2006;26:82-8. http://dx.doi.org/10.1111/j.1440-1789.2006.00638.x
6. Soldevila M, Calafell F, Andrès AM, Yagüe J, Helgason A, Stefánsson K, et al. Prion susceptibility and protective alleles exhibit marked geographic differences. Hum Mutat. 2003;22:104-5. http://dx.doi.org/10.1002/humu.9157
7. Nurmi MH, Bishop M, Strain L, Brett F, McGuigan C, Hutchison M, et al. The normal population distribution of PRNP codon 129 polymorphism. Acta Neurol Scand. 2003;108:374-8. http://dx.doi.org/10.1034/j.1600-0404.2003.00199.x
8. Mercier G, Diéterlen F, Lucotte G. Population distribution of the methionine allele at the PRNP codon 129 polymorphism in Europe and the Middle East. Hum Biol. 2008;80: 181-90. http://dx.doi.org/10.3378/1534-617(2008)80[181:PDOTMA]2.0.CO;2
9. Doh-ura K, Kitamoto T, Sakaki Y, Taateishi J. CJD discrepancy. Nature. 1991;353:801-2. http://dx.doi.org/10.1038/353801b0
10. Brandel J-P, Preece M, Brown P, Croes E, Laplanche J-L, Agid Y, et al. Distribution of codon 129 genotype in human growth hormone- treated CJD patients in France and the UK. Lancet. 2003; 362: 128-30. http://dx.doi.org/10.1016/S0140-6736(03)13867-6
11. Furtner M, Gelpi E, Kiechl S, Knoflach M, Zangerl A, Gotwald T, et al. Iatrogenic Creutzfeldt-Jakob disease 22 years after human growth hormone therapy: clinical and radiological features. J Neurol Neurosurg Psychiatry. 2008;79:229-31. http://dx.doi.org/10.1136/jnnp.2007.122267
12. Noguchi-Shinohara M, Hamaguchi T, Kitamoto T, Sato T, Nakamura Y, Mizusawa H, et al. Clinical features and diagnosis of dura mater graft-associated Creutzfeldt-Jakob disease. Neurology. 2007;69:360-7. http://dx.doi.org/10.1212/01.wnl.0000266624.63387.4a
13. Yamada M, Noguchi-Shinohara M, Hamaguchi T, Nozaki I, Kitamoto T, Sato T, et al. Dura mater graft-associated Creutzfeldt-Jakob disease in Japan: clinicopathological and molecular characterization of the two distinct subtypes. Neuropathology. 2009;29:609-18. http://dx.doi.org/10.1111/j.1440-1789.2008.00987.x
14. Nozaki I, Hamaguchi T, Sanjo N, Noguchi-Shinohara M, Sakai K, Nakamura Y, et al. Prospective 10-year surveillance of human prion diseases in Japan. Brain. 2010;133:3043-57. http://dx.doi.org/10.1093/brain/awq216
15. Ladogana A, Puopolo M, Croes EA, Budka H, Jarius C, Collins S, et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology. 2005;64:1586-91. http://dx.doi.org/10.1212/01.WNL.0000160117.56690.B2
16. Garruto RM, Reiber C, Alfonso MP, Gastrich H, Needham K, Sunderman S, et al. Risk behaviors in a rural community with a known point-source exposure to chronic wasting disease. Environ Health. 2008;7:31. http://dx.doi.org/10.1186/1476-069X-7-31
17. Diringer H, Braig HR. Infectivity of unconventional viruses in dura mater. Lancet. 1989;1:439-40. http://dx.doi.org/10.1016/S0140-6736(89)90035-4
18. Pocchiari M, Peano S, Conz A, Eshkol A, Maillard F, Brown P, et al. Combination ultrafiltration and 6 M urea treatment of human growth hormone effectively minimizes risk from potential Creutzfeldt-Jakob disease virus contamination. Horm Res. 1991;35:161-6. http://dx.doi.org/10.1159/000181894
19. Yunoki M, Tanaka H, Urayama T, Hattori S, Ohtani M, Ohkubo Y, et al. Prion removal by nanofiltraion under different experimental conditions. Biologicals. 2008;36:27-36. http://dx.doi.org/10.1016/j.biologicals.2007.04.005
20. Cardone F, Simoneau S, Arzel A, Puopolo M, Berardi VA, Abdel-Haq H, et al. Comparison of nanofiltration efficacy in reducing infectivity of centrifuged versus ultracentrifuged 263K scrapie-infected brain homogenates in "spiked" albumin solutions. Transfusion. 2011. Epub ahead of print. http://dx.doi.org/10.1111/j.1537-2995.2011.03425.x
21. Gregori L, Gurgel PV, Lathrop JT, Edwardson P, Lambert BC, Carbonell RG, et al. Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins. Lancet. 2006;368:2226-30. http://dx.doi.org/10.1016/S0140-6736(06)69897-8
22. Heger A, Bailey A, Neisser-Svae A, Ertl M, Römisch J, Svae TE. Removal of prion infectivity by affinity ligand chromatography during OctaplasLG manufacturing-results from animal bioassay studies. Vox Sang. 2011. Epub ahead of print. http://dx.doi.org/10.1111/j.1423-0410.2011.01563.x
23. Piccardo P, Cervenakova L, Vasilyeva I, Yakovleva O, Bacik I, Cervenak J, et al. Candidate cell substrates, vaccine production, and transmissible spongiform encephalopathies. Emerg Infect Dis. 2011;17:2262-9. http://dx.doi.org/10.3201/eid1712.110607
24. Fichet G, Comoy E, Duval C, Antioga K, Dehen C, Charbonnier A, et al. Novel methods for disinfection of prion-contaminated medical devices. Lancet. 2004; 364: 521-6. http://dx.doi.org/10.1016/S0140-6736(04)16810-4
25. Fichet G, Antioga K, Comoy E, Deslys JP, McDonnell G. Prion inactivation using a new gaseous hydrogen peroxide sterilization process. J Hosp Infect. 2007;67:278-86. http://dx.doi.org/10.1016/j.jhin.2007.08.020
26. Fichet G, Harrison J, McDonnell G. Reduction of risk of prion transmission on surgical devices with effective cleaning processes. Zentr Steril. 2007;15:418-37.
27. Orrú CD, Wilham JM, Raymond LD, Kuhn F, Schroeder B, Raeber AJ, et al. Prion disease blood test using immunoprecipitation and improved quaking-induced conversion. MBiol. 2011; 3: e00078-11 [cited 2012 Mar 31]. http://mbio.asm.org/content/2/3/e00078-11.full
28. Orrú CD, Wilham JM, Vascellari S, Hughson AG, Caughey B. New generation QuIC assays for prion seeding activity. Prion. 2012;6. Epub ahead of print.